Reuters logo
BRIEF-Inovio Ebola vaccine demonstrates robust immune responses with favorable safety profile in expanded clinical trial
April 11, 2017 / 1:22 PM / 8 months ago

BRIEF-Inovio Ebola vaccine demonstrates robust immune responses with favorable safety profile in expanded clinical trial

April 11 (Reuters) - Inovio Pharmaceuticals Inc

* Inovio Ebola vaccine demonstrates robust immune responses with favorable safety profile in expanded clinical trial

* Inovio Pharma - results across both stages of trial showed that 95 pct of evaluable subjects generated an Ebola-specific antibody immune response

* Inovio Pharmaceuticals Inc - Inovio’s Ebola vaccine was well-tolerated with a favorable safety profile compared to viral vector-based Ebola vaccines

* Inovio Pharmaceuticals Inc - plan to meet with regulators this year regarding a path forward for licensure of Ebola product Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below